Get started
Author

Praharshinie Rupasinghe

Observed names: P Rupasinghe, P. Rupasinghe, Padmanayakege Chamithra Dilshani Rupasinghe, Rupasinghe, P.
ORCID: 0000-0002-9858-8935
Observed ORCID: 0000-0002-9858-8935
OpenAlex ID: A5057456733
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial
2025 · Lorenzo Guglielmetti, Uzma Khan, et al. · The Lancet Respiratory Medicine · 33
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial
2021 · L. Guglielmetti, E. Ardizzoni, et al. · Trials · 32
PDF
Balancing access to BPaLM regimens and risk of resistance
2022 · Annelies Van Rie, Timothy Walker, et al. · The Lancet Infectious Diseases · 30
PDF
Refined understanding of the impact of the Mycobacterium tuberculosis complex diversity on the intrinsic susceptibility to pretomanid
2024 · Praharshinie Rupasinghe, Rabab Reenaers, et al. · Microbiology Spectrum · 18
PDF
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial
2023 · S. B. Patil, M. Tamirat, et al. · Trials · 13
PDF
Reduced critical concentration might not have improved MGIT-based DST’s sensitivity to rifampicin
2024 · Praharshinie Rupasinghe, Azka Ashraf, et al. · Antimicrobial Agents and Chemotherapy · 6
PDF
In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis
2025 · Praharshinie Rupasinghe, Nabila Ismail, et al. · Antimicrobial Agents and Chemotherapy · 4
End of treatment and 12-month post-treatment outcomes in patients treated with all-oral regimens for rifampicin-resistant tuberculosis in Ukraine: a prospective cohort study
2025 · Vini Fardhdiani, Olena Trush, et al. · PLOS Global Public Health · 3
Middlebrook 7h11 Reduces Invalid Results and Turnaround Time of Phenotypic Drug-Susceptibility Testing of M. Tuberculosis
2022 · Praharshinie Rupasinghe, Jens Vereecken, et al. · International Journal of Mycobacteriology · 2
PDF
Bedaquiline, Delamanid, Linezolid and Clofazimine for the Treatment of Rifampicin- and Fluoroquinolone-Resistant Tuberculosis (endTB-Q): A Phase 3, Open-Label, Multicentre, Randomised, Controlled, Stratified, Non-Inferiority Trial
2025 · Lorenzo Guglielmetti, Uzma Khan, et al. · SSRN Electronic Journal · 1
National and state-level variation and temporal trends in the cost of five CMS-negotiated oral cancer drugs in Medicare Part D, 2014–2023.
2026 · Padmanayakege Chamithra Dilshani Rupasinghe, Bian Liu, et al. · JCO Oncology Practice
PDF
endTB-Q trial: a caveat on confounding by baseline drug resistance – Authors' reply
2026 · Lorenzo Guglielmetti, Maelenn Gouillou, et al. · The Lancet Respiratory Medicine
Extensively Drug-Resistant Tuberculosis with Conflicting Resistance Testing Results, Lesotho
2025 · Kwonjune J. Seung, Meseret Asfaw, et al. · Emerging infectious diseases
Identifying and addressing the gaps impeding fast and accurate phenotypic drug-susceptibility testing of Mycobacterium tuberculosis
2024 · Praharshinie Rupasinghe
Re-evaluation of Critical Concentrations of Antituberculosis Fluoroquinolones in the Mycobacteria Growth Indicator Tube 960 System
2023 · Praharshinie Rupasinghe, Michele Driesen, et al. · International Journal of Mycobacteriology
Works count: 18
Citation count: 142
H-index: 6
I10-index: 5
Year
Topic
Type